Policy & Regulation
Care Access Research Collaborates with AstraZeneca on Phase III Clinical Trial for COVID-19 Long-Acting Antibody Combination
26 January 2021 - - US-based research organization Care Access Research has forged a collaboration with British-Swedish biopharmaceutical company AstraZeneca (OTC: AZNCF) to accelerate a clinical trial in the US for AZD7442, AstraZeneca's long-acting monoclonal antibody combination for the potential prevention of COVID-19, the company said.

Care Access is supporting the Phase III clinical trial called STORM CHASER, which will assess the safety and efficacy of AZD7442 for post-exposure prophylaxis and pre-emptive treatment in approximately 1,125 participants in the US and UK.

Participants in this trial will include adults over 18 years of age following exposure to SARS-COV-2 and who are therefore at appreciable risk of developing COVID-19.

The trial will include people living or working at long-term care facilities as well as industrial and military settings.

The Care Access and AstraZeneca teams are collaborating to rapidly develop, deploy, and manage clinical research sites across the country, using Care Access' innovative Mobile Sites On Demand capability to bring research capabilities including people, equipment, software, and processes to places and communities that would otherwise have limited access to clinical trials, such as long term care facilities.

Care Access is uniquely equipped with the operational systems and staff required to mobilize the entire clinical research operation and bring it directly to patients.

This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority in partnership with the Department of Defense; Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense; under Contract No. W911QY-21-9-0001.
Login
Username:

Password: